MAP in Pregnancy & Preeclampsia

How MAP changes during a normal pregnancy

Pregnancy is one of the most dramatic cardiovascular states the body goes through. Cardiac output rises 30–50% from baseline, driven by both a faster heart rate (typically 15–20 bpm above pre-pregnancy) and increased stroke volume. At the same time, progesterone relaxes vascular smooth muscle and the new, low-resistance placental circulation adds to SVR reduction. The net result is that MAP falls through the first and second trimesters — it doesn't rise, despite a 40–45% expansion in blood volume. The increased volume goes into a bigger, more compliant vascular bed.

Preeclampsia — when MAP goes the wrong way

Preeclampsia complicates 2–8% of pregnancies. The definition: new-onset hypertension (SBP ≥ 140 or DBP ≥ 90 mmHg) after 20 weeks, plus proteinuria or end-organ dysfunction. The underlying problem is not primarily hypertension — it's abnormal placentation. Incomplete remodelling of the spiral arteries in the first trimester produces a poorly perfused, ischaemic placenta that releases anti-angiogenic factors (particularly sFlt-1) into the maternal circulation. Those factors damage maternal endothelium throughout the body, causing pathological vasoconstriction, capillary leak, and coagulation activation — driving MAP upward rather than following the normal pregnancy fall.

First-trimester MAP above 85–90 mmHg is an early predictive signal, particularly when combined with abnormal uterine artery Doppler and elevated sFlt-1:PlGF ratio. First-trimester combined screening using these markers can identify high-risk women who benefit from low-dose aspirin started before 16 weeks — the only intervention with good evidence for preeclampsia prevention.

Treatment — the over-treatment problem

The goal in preeclampsia is not to achieve a normal adult MAP. It's to prevent catastrophic events — hypertensive stroke, eclampsia, placental abruption — while maintaining enough uteroplacental perfusion pressure for the fetus. Over-treating to a low target risks fetal compromise. The target is moderate, not normal.

Most guidelines recommend targeting 130–150 / 80–100 mmHg (MAP roughly 97–117 mmHg). Acute drops of more than 20–25% of baseline MAP should be avoided — they can trigger fetal bradycardia from placental hypoperfusion.

HELLP syndrome

HELLP (Haemolysis, Elevated Liver enzymes, Low Platelets) complicates 0.2–0.8% of all pregnancies and 10–20% of severe preeclampsia cases. MAP management principles are the same as for severe preeclampsia, but the clinical picture is more complex: coagulopathy limits invasive procedures, hepatic subcapsular haematoma risk means avoiding anything that raises intra-abdominal pressure, and thrombocytopaenia requires careful surgical planning.

Delivery is the only definitive treatment. At ≥ 34 weeks or with severe maternal features (platelets below 50,000, uncontrolled BP, deteriorating organ function), delivery is recommended regardless of gestational age. Corticosteroids — dexamethasone or betamethasone — are given for fetal lung maturation before 34 weeks and may transiently improve platelet counts in HELLP.

Postpartum — not over at delivery

BP typically rises in the first 3–5 days postpartum as the oedema fluid accumulated during pregnancy mobilises back into the vascular space — preload rises, and so does MAP. In women with preeclampsia, this postpartum rise can push MAP higher than intrapartum levels, triggering new complications including pulmonary oedema and hypertensive encephalopathy.

Postpartum preeclampsia — new-onset hypertension appearing more than 48 hours after delivery, up to 6 weeks postpartum — is significantly underrecognised. Women discharged after apparently uncomplicated deliveries can develop severe-range hypertension and eclampsia at home. Any woman presenting with severe headache, visual disturbance, or new hypertension in the 6 weeks after delivery needs urgent assessment for postpartum preeclampsia.

Longer term: women with a history of preeclampsia have a 4-fold increased lifetime risk of cardiovascular disease. Delivery solves the immediate problem but these women need appropriate long-term cardiovascular follow-up.

Key takeaways

• Pregnancy normally lowers MAP — nadir at 20–24 weeks, 65–75 mmHg. This is physiological, not pathological
• A rising MAP in the second trimester, or any rise above pre-pregnancy baseline, warrants evaluation for gestational hypertension or preeclampsia
• Preeclampsia: ≥140/90 after 20 weeks plus proteinuria or end-organ features. Root cause is abnormal placentation, not just hypertension
• Treatment target is 130–150/80–100 mmHg — not normal adult MAP. Over-treatment risks fetal compromise from placental hypoperfusion
• Severe preeclampsia (≥160/110) needs antihypertensive treatment within 30–60 minutes to prevent stroke
• ACE inhibitors and ARBs are contraindicated in pregnancy without exception
• HELLP is a severe variant — delivery is the only definitive treatment
• Postpartum preeclampsia is real and underrecognised — continue monitoring BP for 6 weeks after delivery

Sources & references

• Brown MA et al. ISSHP classification, diagnosis and management of hypertensive disorders of pregnancy. Pregnancy Hypertens 2018
• ACOG Practice Bulletin No. 222. Gestational Hypertension and Preeclampsia. Obstet Gynecol 2020
• NICE NG133. Hypertension in Pregnancy. 2019 (updated 2023)
• Rolnik DL et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017 (ASPRE).